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“If you can’t explain it simply, you don’t understand it well enough”
– Albert Einstein

ABSTRACT
Diabetic foot ulcers (DFU) are one of the most debilitating complication of diabetes that 
adversely impacts the health, economics and quality of life of the afflicted individual. 
The primary pathogenic factor of DFU is hyperglycemia, and its negative effects on 
normal signaling pathways is still being investigated. As such, there is no specific 
therapy that could target the underlying dysregulations caused by hyperglycemia. So, 
it is important to delve into various pathways that are altered by hyperglycemia in 
diabetic foot in order to successfully establish novel treatment paradigms.
Wound healing consists of various phases where different cellular processes such as 
cell proliferation, migration, angiogenesis and apoptosis coordinate to achieve a swift 
healing of the wound. In my thesis, I have investigated several signaling pathways 
that play key roles in wound healing and are profoundly disturbed by hyperglycemia 
in diabetes. 
Notch signaling pathway is an important pathway where receptors and ligands from 
juxtaposed cells activate signal transduction. Upon activation, an intracellular domain 
of Notch (NICD) translocates to the nucleus and initiates the transcription of specific 
targets to control cell proliferation, cell migration, angiogenesis, differentiation and 
apoptosis. In paper-I, we show that Notch1 is activated in human and rodent skin and 
several processes central to wound healing are impaired in response to hyperglycemia 
in a Notch1 dependent manner. Mechanistically, we show that hyperglycemia activates 
a Dll4-Notch1 feedforward loop that impairs wound healing in diabetes. Inhibition 
of Notch signaling by chemical and genetic approaches improved wound healing in 
diabetic mice significantly. 
IGF-I is a growth hormone that is expressed in every cell of our body. The circulating 
IGF-I is however derived mainly from the liver. IGF-I promotes wound healing and 
its levels are decreased in diabetic wounds. However, the contribution of circulating 
IGF-I to wound healing is unknown. In Paper II, we generated a liver-specific IGF-I 
knockout mice and induced diabetes in these mice to study the effect of liver-derived 
IGF-I on wound healing. We found that the lack of liver-derived IGF-I did not affect 
healthy wound healing. Although  diabetes delayed wound healing, there was no dif-
ference between knock-out mice and control mice. In addition, the processes contri-
buting to wound healing were not altered by the liver-derived IGF-I deficiency. In 
summary, we found that a lack of liver-derived IGF-I did not affect wound healing. 
Future therapies using IGF-I can be designed to be delivered locally since systemic 
IGF-I therapy is known to carry risks of unfavorable side-effects. 
In papers-III and IV, I have investigated the roles of miRNA-210 and miRNA-34a 
in diabetic wound healing respectively. miR-210 is induced by transcription factor 
HIF-1 in response to hypoxia. miR-210 mirrors HIF function in hypoxia by regulat-
ing important processes such as cell proliferation, migration, apoptosis, metabolism 
and angiogenesis. We found that miR-210 expression is reduced in diabetic wounds 
and locally reconstituting miR-210 using mimics improves diabetic wound healing 
significantly. miR-210 reconstitution led to a reduction in the oxygen consumption rate 
in the wounds that led to a decrease in ROS levels in the wound tissue. This metabolic 
reprogramming by miR-210 ultimately resulted in the improvement in different cel-
lular processes central to wound healing.
miR-34a plays important roles in cell cycle and DNA repair. Importantly, miR-34a 
has been shown to regulate Notch1 directly. Although there are contrasting reports 
on their function in hypoxia and diabetes, their role in diabetic wound healing has not 
been elucidated. In paper-IV, we show that miR-34a was reduced in DFUs and in the 
wounds of diabetic mice. We also found that a long exposure to hypoxia increased 
miR-34a expression exclusively in keratinocytes but exposing cells to high glucose 
decreased its expression in hypoxia. Reciprocally, Notch1 expression levels increased 
in keratinocytes under hypoxic and high glucose levels in a time-dependent manner. 
Finally, we found that diabetic wounds injected with miR-34a mimic showed signifi-
cantly lower expression of Notch1, directly correlating with paper-I, indicating that 
reconstitution of miR-34a could be a potential therapeutic strategy for diabetic wounds.
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11 BACKGROUND
1.1 Diabetes – an epidemic
Diabetes mellitus is a heterogeneous disease characterized by a chronic increase in 
the blood glucose levels. The International Diabetes Federation (IDF) estimates that 
1 in 11 adults are affected by diabetes and 50% of the afflicted are  undiagnosed. It is 
estimated that the number of patients with diabetes will increase to 642 million by 
20401. Obesity, sedentary lifestyle and increase in the age of the population are the 
main contributing factors to the increase in the prevalence of diabetes1. Diabetes has 
an important economic burden that will increase from US $1.3 billion in 2015 to $2.1 
trillion in 20302.
1.1.1 Pathophysiology of diabetes and its complications
Diabetes is broadly classified as type 1 diabetes and type 2 diabetes. The type 1 dia-
betes results from a total insulin deficiency caused by the destruction of the pancreatic 
β-cells due to an autoimmune attack3. Type 2 diabetes is characterized by an insuf-
ficient insulin production by the β-cells to maintain normal blood glucose levels and 
insulin resistance3.
Prolonged exposure of cells to hyperglycemia is the major contributor to diabetes-asso-
ciated complications6,7. Increased uptake of glucose by the cells leads to an increased 
mitochondrial ROS production, that results in the 4 damaging pathways common to 
all the complications of diabetes – increased flux through polyol pathway, production 
of Advanced Glycation End-products (AGE), increased production of Protein Kinase C 
(PKC) and the increased production of  hexosamine inter mediates4. Besides, the increase 
in AGE and low-density lipoprotein levels induce ROS production from NADPH oxi-
dase in the endothelial cells5. Hyperglycemia dependent glycosylation of endothelial 
Nitric oxide synthase (eNOS) and an increase in arginase, which competes with eNOS 
for the substrate, leads to decrease in eNOS activity. This leads to the production of 
reactive nitrogen  species6. Ultimately, all of these lead to microvascular complications 
(retinopathy, nephro pathy, and neuropathy) (Figure 1).
2Figure 1. A graphic representation of the different complications of diabetes.
1.2 Wound healing
Healing of a wound is a complex process coordinated by various molecular events 
leading to wound closure and scar formation7,8,9,10. The events that occur immediately 
after a cutaneous injury can be divided into four overlapping phases: coagulation 
and hemostasis, inflammation, proliferation and remodeling7,8. The appropriate and 
co ordinated progression of these processes is critical to a normal and effective wound 
healing. Impairment in wound healing occurs when one or several under lying molecular 
processes in the different phases are deregulated. A brief overview of the molecular 
events during these phases is presented below (Figure 2).
1.2.1 Coagulation and hemostasis
A cutaneous injury damage the epidermal and dermal layers of the skin, exposes the 
underlying tissue, disrupts the blood vessels and results in an outflow of the blood 
into the tissue. Within minutes after the injury, the vascular smooth muscle cells rap-
idly contract and constrict the damaged blood vessels, preventing the leakage of the 
blood10. This is followed by the release of clotting factors from the platelets which 
contributes to the formation of a blood clot, followed by hemostasis. It will further 
provide a provisional matrix for the cells to migrate in the wound7,11. The sequence of 
events during the activation of platelets and formation of the clot provides the tran-
sition to the next phase of healing. For instance, platelets activate the complement 
system and release a variety of growth factors such as platelet-derived growth factors 
(PDGF), epidermal growth factor (EGF) and transforming growth factor-β (TGF-β) 
which act as signaling molecules to recruit neutrophils, macrophages, endothelial cells 
3and fibroblasts8,10. During the formation of the clot, the polymerization of fibrinogen 
to fibrin yields fragments such as fibrinopeptides A and B, which also act as signaling 
molecules to recruit inflammatory cells to the wound7.
1.2.2 Inflammation 
Neutrophils are the first immune cells that arrive at the wound site after hemostasis. 
Various chemokines produced during clotting attract the neutrophils from circulation by 
inducing the expression of adhesion molecules on endothelial cells12. The neu trophils 
adhere to these adhesion molecules, roll along the endothelium and extravasate into 
the wound site12. Neutrophils play an important role in protecting the wound from 
external factors such as bacteria and foreign bodies. They also release cytokines that 
amplify the inflammatory response. In about 3 to 5 days, the neutrophils are cleared 
and monocytes arrive at the wound site12. A lack of adequate levels of immune response 
or prolonged activation of the inflammatory phase could lead to a lack of progression 
to the proliferation phase and hence could affect the wound healing.
1.2.3 Proliferation
This phase is characterized by the migration of fibroblasts to the wound site, secretion 
of matrix components and formation of the granulation tissue. Migration and prolif-
eration of fibroblasts is facilitated by various growth factors like PDGF secreted by 
inflammatory cells. Once in the wound site, fibroblasts in the presence of transform-
ing growth factor-β (TGF-β), attach to the fibrous proteins in the extracellular matrix 
(ECM) and differentiate into myofibroblasts13. The extracellular matrix (collagen, 
hyaluronan, proteoglycans, etc.) produced by the fibroblasts replaces the provisional 
matrix formed by the platelets. This collagen matrix provides the basis for migration 
of more fibroblasts and contributes to the contraction of the wound14. Moreover, the 
hypoxia caused by the disruption of the blood vessels at the wound site stimulates the 
production of vascular endothelial growth factor (VEGF) and fibroblast growth factor 
(FGF) by macrophages15. This promotes the proliferation and migration of endothelial 
cells into the wound with secondary formation of capillaries within the injured site. The 
macrophages, fibroblasts, the nascent endothelium along with the matrix of collagen, 
fibrinogen and fibronectin collectively constitute the granulation tissue16,14. With the 
accumulation of newer collagen matrix, the neovascularization diminishes and as the 
healing proceeds, the granulation tissue matures to form a scar.
1.2.4 Epithelialization and tissue modeling
As the granulation tissue becomes dense, the keratinocytes around the wound edges 
are activated by various chemokines such as interleukin-1 (IL-1) and TGF-β11,17. The 
activated keratinocytes migrate over the injured site and proliferate to induce epider-
mis regenration17. The proliferating fibroblasts in the granulation tissue also produce 
4keratinocyte growth factor (KGF), which activates the migration and proliferation of 
keratinocytes18. This process is called epithelialization and is vital for regeneration of 
the epidermis. Meanwhile, as the granulation tissue matures, the extracellular matrix 
is degraded by matrix metalloproteinases and a new layer of collagen is secreted. 
The newly secreted collagen I has a higher tensile strength compared to the initially 
secreted collagen III and hence, helps retain the toughness and texture of unwounded 
skin after healing12. This remodeling includes even the contraction of the wound 
mediated by fibroblasts14,12. A careful balance between the degradation and synthesis 
of matrix components is important for a successful remodeling of the wound. As the 
wound heals, excess fibroblasts, macrophages and endothelial cells undergo apoptosis 
followed by a decrease of blood flow at the wound site. The remaining granulation 
tissue ultimately matures into a scar to complete the wound healing process.
Figure 2. A flow diagram showing the different stages of wound healing.
51.3 Diabetic wounds
1.3.1 Molecular aspects of impaired wound healing in diabetes
The factors that contribute to impairment in wound healing in diabetes are complex. 
That includes various intrinsic (neuropathy, angiopathy, hyperglycemia) and extrinsic 
factors (infection, pressure on the wound site)7. Beside the traditional “pathogenic 
triad” that comprise neuropathy, ischemia and trauma, there are several other players 
that contribute to impaired wound healing in diabetes.
1.3.2 The pathogenic triad
Neuropathy – remains the primary cause for more than 60% of the diabetic foot 
ulcers19. Nerve cell damage affects the lower extremities in several ways20. Sensory 
neuropathy is often manifested by a lack of sensation in patients where trauma is left 
unnoticed, which progressively worsens due to repeated physical stress. The loss of 
motor neurons creates an imbalance between the flexion and extension of the affected 
foot. This could lead to anatomic foot deformities that cause abnormal pressure points7. 
Autonomic neuropathy leads to dysfunctional sweat glands and the resulting dryness 
of the feet that makes the skin more fragile19. 
Vascular abnormalities – Both macrovascular disease21 and microangiopathy contrib-
utes to lower blood flow to the wound area. Patients with diabetes also have impaired 
mobilization of bone marrow-derived endothelial progenitor cells (EPC) and defective 
docking to the wound area (Figure 3)22,23.
Trauma – Physical trauma is frequently the initiating factor in the development of a foot 
ulcer. Because of the lack of sensory input, a trauma may go unnoticed. Continuous 
pressure on a deformed area with lack of sensation can also end up in an ulcer7. 
1.3.3 Other molecular factors affecting diabetic wound healing
Infection is also an important pathogenic factor that contributes to delay in the healing 
of an established foot ulcer. Infections are also the primary reasons for amputations 
in patients with diabetic foot ulcers24. Patients with diabetes are more susceptible to 
infections due to several immune defects9 i.e. endothelial dysfunction that prevents 
proper homing of inflammatory cells24, repression of the function of macrophages and 
neutrophils (Figure 3)25. Pleotropic growth factors such as IGF-I, TGF-β and PDGF, 
which are important for the migration and proliferation of endothelial cells, keratino-
cytes and fibroblasts have been shown to be reduced in biopsies from human diabetic 
foot ulcers (Figure 3)26-28. 
Moreover, cell-type specific growth factors such as nerve growth factor (NGF), 
keratinocyte growth factor (KGF) have also been found to be decreased in the patients 
with diabetes ulcers 29,30. Expression of matrix metalloproteinases (MMPs) is also 
6impaired in diabetes and contributes to defective wound healing31,25. MMPs play a 
vital role in regulating the degradation of extracellular matrix (ECM) and for making 
the growth factors and other molecules to be available for the cells that participate in 
wound healing. Epigenetic factors influence the progenitor cells in the bone marrow 
which results in a pro-inflammatory phenotype in macrophages, adversely affecting 
wound healing in diabetes32.
Figure 3. Depiction of defective wound healing in diabetes with impaired proliferation of 
fibroblasts, a decrease in immune cells and poor signaling that leads to reduced recruit-
ment of EPCs and poor angiogenesis. 
1.3.4 Importance of targeting signaling pathways in diabetic 
wound healing
Progress has been made in the management of diabetic foot ulcers in recent times by 
different approaches such as management of infection, offloading33-35. 
There is however a lack of a specific therapy for diabetes foot ulcers. However several 
specific defects were identified in different phases of wound healing in diabetes such 
as inflammation36,37, angiogenesis38,39, hypoxia response40,41,42 and epithelialization43,26 
and hopefully will generate targeted therapies.
71.4 Notch signaling pathway
Notch is an important signaling pathway that plays vital role in cell fate decisions in 
the developmental program of the metazoans. Notch signaling regulates cell prolifera-
tion, differentiation, angiogenesis and apoptosis in a context dependent manner44,45. The 
importance of Notch pathway is highlighted in various developmental diseases caused 
by genetic loss of Notch or the components of the pathway. More importantly, aber-
rantly activated Notch signaling in adults may also form the pathogenesis of various 
diseases including hereditary diseases, cancer, cardio vascular disease, and kidney dis-
ease46. Thus, Notch has become an important therapeutic target of clinical significance.
The Notch pathway has a unique mechanism of signal transduction. The pathway 
is activated by cell-to-cell contact of Notch receptors and its corresponding ligands 
(Figure 4). In mammals, the Notch receptor consists of 4 paralogues (Notch 1 to 4) 
and ligands Delta-like (Dll1, Dll3 and Dll4) and Jagged (Jag1 and Jag2)44. Upon acti-
vation, the receptor undergoes a series of cleavages that results in an activated intra-
cellular domain of Notch (NICD) that directly translocates into the nucleus where it 
displaces the transcriptional repressor bound to DNA binding protein CBF1-suppressor 
of Hairless-LAG1 (CSL) and along with co-activator Mastermind-like transcriptional 
activator 1 (MAML1), induces the transcription of target genes45. The series of cleav-
ages upon ligand binding is mediated first by ADAM proteases which cleaves the 
Notch receptor at site S2 leaving an inter mediate called Notch Extracellular Truncation 
(NEXT). This becomes the substrate for γ-secretase enzyme, that cleaves the NEXT 
progressively from site S3 into the middle of the transmembrane domain at S4 result-
ing in the generation of NICD44. The recruitment of NICD to CSL displaces the core-
pressor, that is initially bound to CSL. The trimeric complex formed by CSL, NICD 
and MAML1 is essential for Notch-dependent transcription. In addition, this complex 
recruits Ski-interacting protein (SKIP), a transcriptional coregulator, to the promoter. 
In turn, MAML1 recruits the histone acetylase p300, which promotes the assembly 
of initiation and elongation complexes47. Assembly of these complexes induces the 
transcription of Notch target genes such as Hes and Herp family of transcription fac-
tors, cell cycle regulator p21 and Notch regulated ankyrin-repeat protein (Nrarp)48,49.
1.4.1 Functions of Notch1 pathway
Notch signaling pathway is one of the most evolutionarily conserved pathways among 
metazoans. It is prominently active during development and in the self-renewing tis-
sues of adults and influences vital cell fate decisions by controlling gene expression45. 
However, Notch signaling is strictly context specific, which is underlined by the distinct 
functions and effects of its ligands and receptors. In addition, any small changes – 
increase or decrease in its expression levels may lead to disease conditions50. Moreover, 
the cooperation of Notch with other signaling pathways in a particular milieu dictates 
the amplitude and extent of its signaling51,52.
8Notch signaling operates through different modes of actions during development. For 
instance, during cell division, Notch is capable of amplifying its signaling differentially 
and promote asymmetric inheritance of its ligands in the daughter cells to promote 
lineage specification47,53-56. Notch signaling can also segregate different populations of 
cells through induction of Notch receptor and ligand in corresponding different popu-
lations through boundary resolution57,58. In addition, Notch also autoregulates itself 
in the same cell using cis-inhibition, where the receptor is inhibited by the ligands 
produced by the same cell59,60.
Notch is able to switch cells into proliferative and apoptotic states depending on 
the context. However, the ability of Notch to regulate cell cycle is dictated by the 
requirements in differentiation53. Notch also plays important role in angiogenesis. The 
endothelial cells express receptors Notch1, 4 and ligands Delta-like 1, 4 and Jagged1, 
of which Notch1 and Dll4 play crucial role in angiogenic sprouting. The sprouting is 
led by endothelial tip cells which expresses high levels of Dll4 and is located at the 
protruding front directed towards to angiogenic cues61.
1.4.2  Regulation of Notch1 signaling
The Notch signaling pathway is a complex machinery with a seemingly simple activa-
tion mechanism. Apart from the signaling cues, Notch signaling is also regulated by 
factors within as well as from outside of its core machinery. 
Regulation of receptor-ligand interaction – Since each Notch molecule can generate a 
signal by ligand binding once, the foremost regulation of Notch signaling is through the 
availability of the receptors and ligands. Although there may be overlapping expression 
levels of different receptors and ligands in a cell, the spacial and temporal expression 
of receptor and ligand is regulated by various cues and interaction with other signal-
ing pathways, which are still being unraveled44,45.
Regulation by ligand/receptor endocytosis – After engaging with the Notch receptor, 
the ligand undergoes endocytosis. This generates a pulling force, that exposes the site 
of proteolytic cleavage on the receptor. The endocytosis of the ligand is carried out by 
E3 ubiquitin ligases Neuralized (NEUR) and Mindbomb (MIB). Hence, the levels of 
these ubiquitin ligases in the cells can regulate the extent of endocytosis of the ligands, 
thereby affecting the signal strength45. 
Receptor glycosylation – Notch receptors are glycoproteins, which means their EGF 
repeats can be modified by glycosylation by O-fucose and O-glucose moieties. The 
amount of fucosylation determines the choice of ligand binding to the receptor and 
hence controls the signaling45. Moreover, fucosylation appears to be essential for Notch 
signaling events that requires regulation by Fringe glycotransferases, enzymes that 
extend O-fucose with more sugar moieties62.
9Figure 4. (A) Schematic representation of the induction of Notch signaling pathway; 
(B) The organization of the domains of Notch receptor and Dll4 ligand. 
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Other regulatory factors – NICD stability is tightly regulated by the phosphorylation of 
the PEST domain which targets NICD to proteasome degradation upon recruitment of 
the SCF/Sel10/FBXW7 E3 ubiquitin ligase complex63. NICD trans activation activity 
is not only regulated by the availability of CSL and co-activators that are recruited to 
the promoter of Notch1 target genes, but also regulated by crosstalk with other signal-
ing pathways, such as HIF-1 52 and FIH-164. Apart from that, various epigenetic fac-
tors such as chromatin modification and histone re-arrangements can affect the target 
specificity of Notch signaling47.
1.4.3 Notch1 in diabetes and diabetes complications
Both activated and reduced Notch signaling have been reported in various tissues in 
diabetes. Notch pathway has been shown to be involved in various diabetic complica-
tions, but with different trends. For example, deletion of Notch1 in the podocytes of 
diabetic mice ameliorated the kidney function65. Also, inhibition of Notch by DAPT, 
an inhibitor of γ-secretase, improved neovascularization of diabetic mice after hind-
limb ischemia66. However, in retinal capillaries, diabetes-induced increase in Jag1 
expression leads to Notch1 inhibition in endothelial cells causing diabetic micro-
vasculopathy in the eyes67.
1.4.4 Notch1 and wound healing
Notch signaling plays important roles in the development and postnatal physiology of 
the skin68-73 and is involved in normal wound healing through the regulation of angio-
genesis, cell migration and inflammation37,74. Notch inhibition in non-diabetic animals 
has either no effect75 or even delaying effect74,76 of the wound healing rate. 
Notch signaling is increased in monocytes from patients with type 2 diabetes and in 
wound macrophages from a high-fat diet induced diabetic mouse model which contrib-
utes to the increased inflammation in diabetic wound37. Notch inhibition in macro phage 
improves wound healing in high-fat diet induced diabetic mice37. In this thesis, I have 
also presented our recent findings that hyperglycemia triggers a Dll4-Notch1 feedback 
loop in diabetic skin and local Notch1 inhibition improves healing exclusively in 
diabetic but not in non-diabetic animals77. The beneficial effects of Notch inhibition 
on diabetic wound healing are confirmed in another recent publication78.
1.5 IGF-I signaling pathway
The insulin-like growth factors (IGFs) are a class of molecules homologous to insulin 
and exert pleiotropic effects on almost all cells of the body during fetal, neonatal and 
adult development and homeostasis79,80. Induced by the growth hormone, IGFs mediate 
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long-term actions in terms of cell growth, differentiation and cell survival while insulin 
mainly possess metabolic activity. The importance of IGF signaling is  realized when 
its defective signaling can lead to insulin resistance and metabolic disease.
IGFs are mainly two isoforms IGF-I and IGF-2 and they act as ligands to IGF-I, IGF-2 
and insulin receptors. IGF receptors (IGFR) are also highly homologous to insulin 
receptor. IGFs and insulin can bind to both insulin and IGF receptors with varying 
affinities79. In addition, IGF signaling is regulated by a family of IGF-binding pro-
teins (IGFBPs). There are six types of IGFBPs which are capable of binding IGFs 
with equal or greater affinity than the IGF receptors. A vast majority of IGFs in the 
serum are found to be bound in a ternary complex consisting of IGF, IGFBP and an 
acid labile subunit (ALS). Binding to IGFBPs increases the half-life of IGFs to around 
25 minutes as opposed to free-form which has a half-life of 10 minutes. IGFBP3 is 
the most prevalent binding protein found in the serum with the highest concentration. 
In general, IGFBPs regulates the availability of IGFs that bind to the IGF receptor81.
1.5.1  Physiological roles of IGF-I
Although IGF-I is mainly produced by the liver to act in an endocrine fashion in the 
peripheral organs, every tissue is capable of producing local IGF-I for autocrine or 
paracrine purposes. A detailed description of the roles of IGF-I in different tissues is 
depicted in figure 5. The expression levels of IGF-I has been shown to be higher in 
fetal lung, muscle and stomach than it is postnatally. Moreover, the importance of IGF-I 
signaling during fetal development is highlighted by mutation in IGF-IR resulting in 
both intrauterine and postnatal growth impairment82. The role of IGF-I in fetal devel-
opment is seen as independent of and synergistic to the role of the growth hormone.
IGF-I is produced in peaks that coincides with neural progenitor proliferation and dif-
ferentiation and neurite outgrowth83. In addition, it has been shown that IGF-I could 
cross the blood-brain barrier by the presence of IGF-IR in the brain capillary endothelial 
cells. Other evidences point to the role of liver-derived IGF-I in regulating the clear-
ance of brain amyloid-β levels and its potential implications in Alzheimer’s disease84. 
The role of IGF-I in kidney development and  function is underscored not only by the 
expression of IGF-I and IGF-IR but also by the examples of animal models developing 
renal disease by IGF-I disruption85. Furthermore, administration of IGF-I to rodents 
and humans increases kidney growth, renal blood flow and glomerular filtration rate86. 
IGF-I is very important for the cardiovascular system as well and IGF-I and IGF-IR 
are expressed in the myocardium, aortic smooth muscle cells and endothelial cells. 
Studies have shown that IGF-I is a potent vasodilator and this effect may be partly 
mediated by increased NO release from the endothelium87. Also, insufficient levels of 
IGF-I plays significant roles in vascular diseases such as atherosclerosis88.
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1.5.2  IGF-I regulation in diabetes
It is well-known that low circulating levels of IGF-I are associated with reduced 
insulin sensitivity and risk of glucose intolerance and type 2 diabetes89. Meta-analysis 
of genome-wide data for continuous diabetes-related traits in non-diabetic subjects 
reported two loci, IGF-I and GCKR, with significant association for fasting insulin 
levels90. Moreover, liver-specific IGF-I knockout mice revealed insulin resistance 
and hyperinsulinemia that may be reversed by administering recombinant IGF-I91. 
IGF-I seems to have a glucose-lowering effect similar to that of insulin, since patients 
with type 2 diabetes responded to IGF-I treatment with improved glucose tolerance, 
hyperinsulinemia and hyperlipidemia92. Despite its positive effects, many clinical tri-
als have reported adverse effects such as cataract, renal hypertrophy and neoplastic 
formations from long term recombinant human IGF-I treatment albeit well tolerated 
and easily managed without treatment discontinuation. Hence, care should be taken 
and more efforts should be made to further assess its safety as a long-term treatment 
option for diabetes.
Figure 5. An illustration of the various physiological roles of IGF-I in human body.
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1.5.3 IGF-I and wound healing
As a growth promoting molecule, IGF-I is considered to be important in promoting 
wound healing. Reports have shown that overexpression of locally acting IGF-I under 
K14 promoter improves murine wound healing93. In addition, the effects of IGF-I in 
vitro on keratinocytes and fibroblasts seem to improve proliferation and migration, 
which aids in the healing94-96. Given its deficiency in metabolic diseases, cells isolated 
from diabetic foot ulcers and diabetic mouse wounds had reduced IGF-I levels26,97. 
Moreover, the individual contributions of liver-derived and locally produced IGF-I to 
wound healing is not clear. Evidences from abnormal wound settings such as the ones 
in diabetes is also not helpful since both liver-derived and locally produced IGF-I levels 
are reduced in diabetes. Thus, in my second paper, I have investigated the effects of 
endocrine IGF-I in both normal and diabetic wound healing.
1.6 Hypoxia and hypoxia inducible factors
Hypoxia is a state where the demand for oxygen exceeds its supply. In order to cope 
with such limited oxygen levels, all metazoans have evolved a complex mechanism 
of regulation by a family of proteins called Hypoxia inducible factors (HIF)98,99. HIF 
consists of two subunits, a tightly regulated α subunit and a constitutively expressed β 
subunit. The α subunit exists in three different isoforms. The HIF-1α isoform is ubiqui-
tously expressed whereas HIF-2α and HIF-3α are tissue specific100. While HIF-1 and 
HIF-2 coordinate similar functions, they have also been shown to regulate unique gene 
expression patterns according to their localization101-103. The regulation and function 
of HIF-3 is not clearly understood. The helix-loop-helix-PAS domains in both the α 
and β subunits facilitate hetero dimerization and DNA binding. 
HIF-1α is regulated at various levels to ensure proper oxygen homeostasis. Under 
normal oxygen conditions, HIF-1α protein is hydroxylated at specific proline residues 
by proline hydroxylases (PHDs)104,105. In the presence of oxygen, iron and 2-oxogu-
tarate, PHDs use one atom from molecular Oxygen to insert into the proline residues 
and the other atom combines with α-oxoglutarate to form succinate and CO2. In its 
hydroxylated form, HIF-1α binds to the ubiquitin ligase von Hippel Lindau (VHL), 
which targets it for proteasomal degradation104,105. HIF function is also regulated by 
factor inhibiting HIF (FIH-1) by the hydroxylation of asparagine residues of HIF-1α 
to prevent the recruitment of transcriptional coactivators106,107. During hypoxia, lack 
of oxygen renders the hydroxylases inactive and a stabilized HIF-1α dimerizes with 
HIF-1β and binds to specific regions in the DNA called hypoxia responsive elements 
(HRE). This is followed by the activation of the transcription of genes involved in 
angiogenesis, erythropoiesis, proliferation and glucose metabolism and helps the 
cells adapt to the hypoxic environment98,99,108. Moreover, HIF-1 also regulates a host 
of microRNAs and long non-coding RNAs such as miR-23, miR-24, miR-26, miR-
27, miR-103, miR-107, miR-181, miR-210, miR-213, H19, MALAT1, HOTAIR and 
FALEC, which are used as fine-tuning mechanisms of the hypoxia response109. 
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1.6.1 HIF-1 and wound healing
A nascent wound microenvironment experiences acute hypoxia due to the  damage 
to the blood vessels and a rapid increase in the consumption of oxygen by the cells 
metabolically activated to heal the wounds. This leads to the stabilization of HIF-1α 
which plays important roles in promoting wound healing. However, HIF-1 activation 
has been shown to be impaired in diabetic wounds110, 111. Accordingly, HIF-1 protein 
levels and function are downregulated in the wounds of diabetic mice112. This also 
corresponds to low HIF-1 levels in the biopsies from patients with diabetic foot ulcers 
as compared to those from control subjects112. Moreover, local stabilization of HIF-1 
on the wounds of diabetic mice through chemical inducers has been proven to be 
effective in improving wound healing110. Hence, a deep insight on the mechanisms of 
HIF-1 inhibition in diabetes would unlock a potential therapeutic strategy for treating 
chronic diabetic wounds.
1.7 MicroRNAs and wound healing
Of all the genomic DNA, only about 2% of it is encoded into proteins. About 97 to 
98% of it is transcribed into non-protein coding RNAs which consists of two broad 
categories of small and long non-coding RNAs based on their lengths. microRNAs 
(miRNAs) are a major class of small RNAs which are 21-23 nucleotide long oligonu-
cleotides that negatively regulates gene transcription by translation inhibition or mRNA 
degradation113-115. In some cases, miRNAs can also bind to the open reading frame 
(ORF) sequences and the 5’-UTR, leading to gene activation rather than repression116. 
miRNA-based regulation of gene expression is being unraveled in every biological 
process from development to tissue homeostasis. In addition, dysregulated miRNA 
expression has been shown to be pathogenic for various diseases. 
1.7.1 microRNA biogenesis
miRNAs are transcribed from miRNA genes by RNA polymerase II into about 1kb long 
transcript called primary-miRNA (pri-miRNA) (Figure 6)113,114. This transcript is then 
processed to a 65 nucleotide long premature-miRNA (pre-miRNA) by a complex called 
microprocessor consisting of an RNase III enzyme Drosha and its co factor DGCR8. This 
transcript is then transported to the cytoplasm through a Ran-GTP dependent nuclear 
export factor, Exportin-5. In the cytoplasm, the  pre-miRNA is further processed by 
another RNase III enzyme Argonaute (AGO) to form a miRNA-induced silencing 
complex (miRISC). This involves the cleavage of one of the strands of the duplex and 
the other one forming the mature miRNA113-115.
1.7.2 microRNAs in wound healing
Since the discovery of miRNA’s role in diseases, an increasing number of reports have 
revealed the importance of miRNAs in regulating different physiological processes 
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including wound repair. Studies have shown that miRNAs are involved in each stage 
of wound healing. For example, miR-146a and miR-155 produced by macrophages 
regulates differentiation of monocytes to macrophages117,118. miR-146a has even been 
implicated in the inflammatory phase of diabetic wounds in mice. An array of miRNAs 
including miR-21, -203 and -205 has been associated with migration and prolifera-
tion of keratinocytes116. Therefore, it is of interest to explore the possibility of more 
miRNAs that could regulate processes in wound healing and to study their potential 
role in the pathogenesis of diabetic foot ulcers. In my thesis, I have investigated the 
role of miR-210 and miR-34a in diabetic wound healing.
1.7.3 microRNAs regulated by hypoxia and HIFs
microRNAs that are induced in response to hypoxia are called “hypoxamiRs”. There 
are different modes of regulation of positive and negative feedback loops of miRNAs 
acting upstream as well as downstream of HIF and sometimes even independent of 
HIF to reinforce hypoxic adaptation. For instance, in endothelial cells, miR-424 sta-
bilizes HIFα isoforms through targeting cullin2 to promote angiogenesis119. miRNAs 
such as miR-20b and miR-199a, which normally target HIF transcript to repress its 
expression, are repressed in hypoxia120,121. An example of negative feedback regula-
Figure 6. A description of microRNA biogenesis.
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tion is hypoxamiR-155, which is induced by HIF in hypoxia and it contributes to 
resolution of HIF effects in intestinal epithelial cells by targeting HIF transcript dur-
ing prolonged hypoxia122.
It is also becoming clear that other transcription factors apart from HIF can also regulate 
miRNA expression during hypoxia. For example, p53, which is induced by hypoxia 
promotes miR-34, miR-15a and miR-16a expression123. Hypoxia can also induce 
NF-κB, a transcription factor that controls inflammation. miRNAs such as miR-146a 
and miR-21 are induced by NF-κB, which regulates inflammation in hypoxia123. Among 
all of the hypoxia-induced miRNAs, the miRNA-210 stands out as the most robust 
hypoxamiR regulated by HIF. miR-210 not only mirrors HIF function by performing 
synergistic functions, but also regulates HIF expression in different contexts. I have 
expanded on the role of miR-210 below.
1.7.4  microRNA-210
Also known as the master hypoxamiR, miR-210 is regulated by both HIF-1 as well 
as HIF-2124. The HRE element found 40bp upstream of the transcription start site of 
miR-210 is highly conserved across species, highlighting the importance of its regu-
lation under hypoxia during evolution. It is also noteworthy that adjacent to the HRE 
elements, there are a number of binding sites for other transcription  factors including 
E2F1, Oct4 and PPARγ, which may indicate its role in cell cycle, metabolism and 
stem cell biology where hypoxia plays a vital role124. 
1.7.4.1 Functions of miR-210
The main function of HIF in hypoxia is to conserve energy and reduce oxidative stress 
by inhibiting the TCA cycle and inducing glycolytic enzymes. To that effect, miR-210 
reflects HIF function non-redundantly by downregulating iron-Sulphur cluster scaf-
fold proteins (ISCU) 125. Iron-Sulphur clusters are essential components of TCA cycle 
enzymes including aconitase and mitochondrial complexes I, II and III 126. miR-210 
further alters mitochondrial dynamics in hypoxia by targeting the D-subunit of succi-
nate dehydrogenase (SDHD) 127. SDH is the only enzyme complex taking part in TCA 
cycle, oxidizing succinate to fumarate as well as being part of the electron transport 
chain as complex II. Thus, miR-210 represents a profound fine-tuning mechanism of 
the mitochondrial function mediated by HIF (Figure 7).
The role of miR-210 in angiogenesis is highlighted by its down modulation of the 
receptor tyrosine kinase ligand EphrinA3 in endothelial cells128. However, the role of 
miR-210 in cell cycle progression remains to be a double-edged sword. While it tar-
gets the transcription factor E2F3, which is involved in the G1/S progression129, thereby 
inducing cell cycle arrest, it also downregulates the repressive partner of transcription 
factor c-Myc, MNT, leading to cell cycle progression130. miR-210 also targets DNA repair 
protein RAD52 in hypoxia131. Interestingly, there have also been reports of miR-210 
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being both positive as well as negative regulator of HIF-1α itself in different contexts. 
One report showed miR-210 to repress HIF-1α and promote TH17 cell differentiation, 
thus, reducing the extent of inflammation in an experimental model of colitis132. Another 
report claimed miR-210 to repress Glycerol-3-phosphate dehydro genase 1-like (GPD1-L), 
which indirectly stabilizes HIF-1α by modulating PHD2 levels133.
1.7.4.2 miR-210 and wound healing
From the perspective of wound healing, a study has shown that HIF mediated upregu-
lation of miR-210 repressed keratinocyte proliferation in an ischemic wound model 
in mice134. Further, an interesting study has revealed that by inhibiting both PHD2 
and miR-210 with oligos diabetic wound healing can be improved, although specific 
mechanism is unclear135. Considering the role of HIF in wound healing and given its 
profound regulation of miR-210, it is tempting to investigate further the mechanism 
of miR-210 regulation in diabetic wound healing.
1.7.5  microRNA-34a
miR-34 family of miRNAs consists of three processed miRNAs – miR-34a, miR-34b 
and miR-34c. They are encoded by two different genes – miR-34a is  transcribed as its 
own transcript while miR-34b and miR-34c share a common primary transcript136. While 
Figure 7. A schematic showing the induction and various roles of miR-210 in response 
to hypoxia.
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miR-34b/c is mainly expressed in the lungs, miR-34a is ubiquitously expressed136. In 
the context of cancer, miR-34a is considered as a tumor suppressor since it is a direct 
target of p53 and is a potent inducer of apoptosis137. However,  several studies have 
uncovered various roles for miR-34a in different cellular processes.
1.7.5.1 Functions of miR-34a
The majority of miR-34a targets belong to genes that control cell cycle and DNA 
damage response such as NMYC, CDK4/6, Cyclin E2, MET and Bcl-2 (Figure 8)138,139. 
Naturally, since p53 is mutated/deleted in many types of cancers, miR-34a is also 
inactivated either as a consequence of p53 mutation or as a direct mutation. Moreover, 
miR-34a mediates a feedforward loop with p53 by targeting the NAD-dependent 
deacetylase SIRT1, which acts on p53 itself and represses the expression of various 
apoptotic proteins140. It is reported that apart from p53, miR-34a is also regulated by 
ELK1141. miR-34a regulates B-cell development by targeting Foxp1, which induces 
the differentiation of pro-B-cell to pre-B-cell progenitor142.
There has been conflicting reports of the effect of hypoxia and high glucose on miR-34a. 
While some reports claim that miR-34a is induced in cardiomyocytes and hepatocytes 
exposed to hypoxia-reoxygenation143,144, it seems to be down regulated in the tubular 
epithelial cells of the kidney145. In addition, miR-34a has been shown to be increased 
in the testes, cochlear hair cells, dorsal root ganglion, foot pad tissue, sciatic nerve 
and the serum of diabetic mice and patients146-149. miR-34a was also upregulated in 
the mouse microvascular endothelial cells contributing to impaired angiogenesis in 
diabetes150. Although, miR-34a was reduced in the kidneys of dia betic patients compared 
to that of non-diabetic subjects145.
Interestingly, miR-34a is a direct regulator of Notch pathway by targeting different 
receptors and ligands including Notch1, Jag1, Dll1 (Figure 8)145,151,152. In addition, 
miR-34a regulates inflammation by targeting several pro-inflammatory molecules 
like NF-κB and HMGB1153,154. 
1.7.5.2 miR-34a and wound healing 
The studies on the role miR-34a in wound healing and its effect in diabetes are scarce. 
However, the few studies that do involve miR-34a has surprisingly implicated miR-34a 
in impaired wound healing in diabetes. For example, fibroblasts cultured from DFUs 
seem to be differentially express miR-34a promoting senescence and cell differentia-
tion and inhibiting cell movement and proliferation, resulting in an overall impairment 
of healing155. Furthermore, in venous ulcers, miR-34a assumes a pro-inflammatory 
role by targeting the anti-inflammatory LGR4 in keratinocytes 156. Given its anti-
inflammatory role in various other contexts, it is therefore tempting to declutter the 
exact role of miR-34a in the context of diabetic foot ulcers. 
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Figure 8. A schematic representation of different miR-34a targets and their effect on cellular processes.
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2 AIMS AND OBJECTIVES
The main objectives of my thesis were to understand different mechanisms by which 
hyperglycemia impairs wound healing in diabetes. Using in vitro (primary cell lines) 
in vivo (mouse models) methods together with exploration of wounds from patients 
with diabetes, I specifically focused on the following specific aims:
1. Determine the role of Notch signaling in diabetic wound healing.
2. Understand the role of liver-dervied IGF-I in healthy and diabetic wound healing.
3. Investigate the regulation and function of miR-210 in diabetic wound healing.
4. Uncover the role of miR-34a and its specific regulation in diabetic wound healing.
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3 METHODS
3.1 Animals
C57BL/KsJm/Leprdb (db/db) diabetic mice and their heterozygous control mice were 
obtained from Charles River (Belgium). Db/db mice are a widely used mouse strain to 
study diabetes and its complications. The loss of Leptin receptor by a point mutation 
renders the leptin signaling defective, which leads to obesity in these mice as early as 
6 weeks of age, that worsens gradually. These mice develop obesity, insulin resistance, 
hyperglycemia and hyperlipidemia and features a decrease in plasma insulin at week 
15, indicating β-cell dysfunction. Thus, db/db mice represent a severe type 2 diabetic 
phenotype, suitable to study molecular pathologies underlying diabetic complications157.
Diabetes was induced in KRT14-Cre;Notch1fl/fl and LI-IGF-I-/- mice and their heterozy-
gous littermates with age of 8-10 weeks by injected 50mg/kg Streptozotocin (STZ) 
prepared in sodium citrate buffer (i.p.) daily for 5 consecutive days according to the 
instructions from AMDCC (Animals Models for Diabetes Complications Consortium). 
STZ is a glucosamine-nitrosourea compound, which is used as a chemotherapeutic 
agent in pancreatic cancer. It induces β-cell apoptosis by preferential accumulation 
through entry through GLUT2 transporter due to its structural similarity to glucose158. 
The mice became diabetic 2 weeks after injection. The mice were kept diabetic for 
another 2 weeks before starting the experiment (14-15 weeks).
3.2 Ethical considerations
All studies were performed in accordance with the ethical permits approved by the 
institutional ethical review committee at Karolinska Institutet, Sweden. Skin and 
wound biopsies from patients and controls were obtained after agreeing and provid-
ing their informed consent. 
3.3 Wound model 
Following blood glucose and HbA1c control, the mice were anesthetized with 3% 
isoflurane. The hair at the back of the mice was shaved using an electric shaver fol-
lowed by the application of depilatory cream. The skin was rinsed with alcohol and 
two full-thickness wounds were made extending through the panniculus carnosus on 
either side of the dorsal midline, using a 6mm biopsy punch. For topical treatments: 
paper-I: 100uL of DAPT (100μM), a transparent dressing (Tegaderm) was applied to 
cover the treatment on the wounds. For paper III and paper IV, miR-210 mimic, miR-
34a mimic and their respective controls (0.125 nmol/wound) was injected intradermally 
around the wound edges on the day of wounding and 6 days after wounding. Following 
wounding, the mice were housed individually and injected with buprenorphine (0.03 
mg/kg) (i.p.) for the first 2 days twice a day to relieve any physical distress possibly 
caused by the surgical procedure. 
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For the measurement of the wound healing rate, the wounds were photographed using 
a digital camera every alternate day until 95% closure of the wounds. A circular ref-
erence was used to correct for the distance between the wound and the camera. The 
wound area was calculated using the ImageJ software version 1.32 (N.I.H., U.S.A.), 
corrected for the area of the reference circle and expressed in percentage of initial 
wound area. For analysis of histology, IHC, mRNA, miRNA or protein expression, 
oxygen consumption rate (OCR) measurement, the wounds were harvested 8 days 
after wounding and processed appropriately according to requirement.
3.4 Histology
Histology was performed on formalin-fixed, paraffin-embedded sections (5 µm). 
After deparaffinization and rehydration, the slides were stained with hematoxylin and 
eosin and the granulation tissue area of the wound was measured. Image analysis and 
quantification was performed using smart segmentation feature on Image Pro Premier 
software v9.2 (Media Cybernetics). At least 3 images from each slide were evaluated 
and each condition had 3-5 slides. Granulation was measured as ratio of the number 
of cells to the total area of the granulation layer in an image. 
Masson-Goldner trichrome staining is used in histology to visualize connective tissues 
by using three different stains to color different subsets of tissues. Weigert’s iron hema-
toxylin is used to generate dark blue/black nuclei, Azophloxine and Tungstophosphoric 
acid Orange G is used to stain cytoplasm, erythrocytes and muscles with a red/pink 
and light green SF solution to counterstain connective  tissue including collagen. FFPE 
sections of wounds were deparaffinized with 2 passes in Xylene for 3 minutes each and 
rehydrated in sequential passes of 100% and 95% Ethanol for 3 minutes, 2 times each. 
The slides were treated according to manufacturer’s instructions to obtain Masson-
Goldner Trichrome staining (Merck Millipore). Images of the staining were obtained 
using Leica DM3000 LED fluorescence microscope using the transmitted light. The 
collagen stained areas in the wounds were analyzed and quantified using the Smart 
Segmentation feature on Image Pro Premier software v9.2 (Media Cybernetics). At 
least 2-4 images from 3-4 tissues from each condition were analyzed. Collagen stain-
ing was expressed as the percentage of area stained by collagen (green).
3.5 Fluorescent immunohistochemistry
The tissues to be analyzed were snap-frozen at the time of animal sacrifice and stored 
in liquid nitrogen until use. The tissues were sectioned at 7μm thickness and stored at 
-80 °C until staining. Before the staining, the slides were thawed and fixed sequen-
tially with 50% acetone for 30 s and 100% acetone for 5 min. For FFPE sections, the 
sections were deparaffinized and rehydrated, and antigen retrieval was performed in 
a microwave (800 W for 20 min) by using citrate buffer. The slides were then washed 
with PBS-T (0.1% Tween) three times for 3 min each. The sections were blocked with 
goat serum or 5% BSA in PBS for 30 min at room temperature (RT), then incubated 
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with primary antibodies overnight at 4 °C. After four times washing with PBS-T for 5 
min each, the sections were incubated with fluorochrome-conjugated secondary anti-
body for 1h at RT in the dark. After washing four times for 5 minutes each, the slides 
were treated with 1 μg/mL DAPI (Life Technologies) in PBS for 5 min at RT. The 
FFPE sections were treated with 0.1% Sudan Black-B solution for 10 min to quench 
autofluor escence. The sections were then mounted and stored at 4 °C. The fluorescent 
images were acquired by using a Leica DM3000 LED fluorescence microscope, an 
LSM Meta 510 confocal microscope (Zeiss), or a Leica TCS SP5 confocal microscope 
(Leica Microsystems). Image analysis was performed by using Image-Pro Premier 
(Version 9.2) and ImageJ (Version 1.47) software. 
3.6 Cell culture
Primary human dermal fibroblasts (HDFs) (ATCC, USA) were cultured in Dulbecco’s 
Modified Eagle’s medium (DMEM; 5.5 mM glucose) supplemented with 100 IU/
ml penicillin and streptomycin, and 10% heat-inactivated FBS (Invitrogen). Primary 
human keratinocytes and HDMECs (PromoCell) were cultured in medium provided 
by PromoCell. The cells were maintained in a humidified atmosphere with 5% CO2 
at 37 °C in a cell culture incubator, and passages 4 to 9 were used for experiments. 
Cells were exposed to normal glucose (5.5mM) or high glucose (30mM) conditions 
and cultured under normoxic [21% (vol/vol) O2] or hypoxic (1% O2) conditions in 
Hypoxia Workstation INVIVO2 (MedicalExpo).
3.7 RNA interference and miRNA overexpression
siRNA oligonucleotides against human Notch1, Notch2, Notch3, Notch4, Dll4 and their 
respective negative controls (Sigma, ThermoFisher Scientific) were used. Keratinocytes 
and HDMECs were transfected with siRNAs using Lipofectamine RNAiMAX trans-
fection reagent (ThermoFisher Scientific) or HiPerfect Transfection reagent (Qiagen), 
according to the manufacturer’s protocol. 24 hours after transfection, the cells were 
appropriately treated and harvested. 
HDFs and keratinocytes were transfected with miR-210 mimic and miR-34a mimic 
or negative control mimic respectively using Lipofectamine RNAiMAX (Life 
Technologies) according to manufacturer’s instructions. The cells were harvested 
24-48 hours after transfection, total RNA was extracted and the expression levels of 
miR-210 and miR-34a were analyzed. 
3.8 RNA purification and quantitative RT-PCR
Total RNA, including microRNAs, was extracted from the cells and tissues using a 
miRNeasy RNA extraction kit (Qiagen). To detect mRNA expression, High-Capacity 
cDNA Reverse Transcription Kit (ThermoFisher Scientific) was used. All quantitative 
RT-PCR was performed on a 7300 Real-Time PCR System or QuantStudio 6 and 7 
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Flex Real-Time PCR System (Applied Biosystems) using SYBR Green Master Mix 
or Taqman Gene Expression Assays (ThermoFisher Scientific). The internal controls 
for mRNA expression were PBGD and Actin. 
3.9 MicroRNA detection
TaqMan microRNA Reverse Transcription kit was used to synthesize cDNA for detect-
ing miR-210, snoRNA55 and U6 snRNA using TaqMan miRNA assays (ThermoFisher 
Scientific). U6 and SnoRNA55 snRNA were used as internal controls in cells and 
mouse tissues, respectively. To detect miR-210 expression in human wounds, cDNA 
was produced using TaqMan Advanced miRNA cDNA Synthesis Kit (ThermoFisher 
Scientific) and microRNA expression was detected using TaqMan Advanced miRNA 
assays (ThermoFisher Scientific), where the average of miR-16, miR-23a, and miR-
24 were used as internal controls.
3.10 In vitro migration assay
HDF and keratinocyte migration was studied using the scratch assay. The cells were 
plated in 24-well plates that were coated with collagen (50 µg/uL) overnight and blocked 
with 3% BSA in PBS for 2 hours. At 90% confluency, HDF cells were transfected 
with the miR-210 mimic or negative control mimic as mentioned above. 24 hours after 
transfection, a scratch was generated in each well with a micropipette tip. The cells were 
rinsed and treated with normal (5.5 mM) or high glucose (30 mM) medium supple-
mented with 0.2% FBS and the plates were placed in normoxia or hypoxia. Mitomycin 
C (10 µg/mL) (Roche) was included in the media to prevent cell proliferation. Digital 
pictures were obtained immediately after scratching and after 16 hours using EVOS 
XL Core Cell Imaging System (ThermoFisher Scientific). Images were analyzed using 
ImageJ v1.47 software (N.I.H., Bethesda, MD, U.S.A.). The experiment was done in 
triplicates and 3 images from each replicate were used for analysis. On each image, 
the distance between the two sides of the scratch were measured at certain intervals 
using ImageJ and the mean of distance was calculated. Migration rate was calculated 
as the difference between the mean of distances at 0 hour (Distance_0h) and 16 hours 
(Distance_16h) divided by the distance at 0 hour ((Distance_0h – Distance_16h)/
Distance_0h). The migration rate for each condition was expressed as percentage to 
the control condition and was expressed as Relative Migration.
3.11 Cell proliferation assay
To measure the effect of miR-210 mimic on proliferation, HDF cells were seeded in 
6 cm2 dishes and were transfected with miR-210 mimic or negative control mimic as 
mentioned above. After 24 hours, the cells from each condition were trypsinized and 
plated on to 96-well plates. 24 hours after seeding, the cells were treated with nor-
mal (5.5 mM) or high (30 mM) glucose levels in serum-free media and placed under 
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hypoxic or normoxic conditions. Cell proliferation was measured the next day using 
the BrdU Cell Proliferation ELISA kit (Abcam; ab126556). BrdU (provided with 
the kit) was added 16 hours before fixing the cells. After fixation, standard protocol 
according to the manufacturer was performed to measure the proliferation of cells and 
were expressed in terms of the percentage of BrdU incorporation. 
3.12 Measurement of oxygen consumption rate by 
Seahorse
The effect of miR-210 on the oxygen consumption rate (OCR) in fresh wound tis-
sue and cells was measured using the Seahorse XF Analyzer (Agilent Technologies). 
The sensor cartridges used for measuring the oxygen flux was equilibrated in an XF 
Calibrant (Agilent Technologies) 16-24 hours before the experiment in a 0%-CO2 
37 °C incubator. The granulation tissue from the wound was carefully dissected and 
rinsed with unbuffered Krebs-Henseleit buffer (KHB) media. The tissue was placed at 
the bottom of the XF24 Islet Capture Microplate (Agilent technologies) and covered 
with a mesh. 450µL KHB medium was added to each well containing the tissue and 
equilibrated in a 0%-CO2 incubator for 30 minutes. Then, the cartridge was placed on 
the assay plate and run in the XF analyzer using an optimized protocol to measure 
basal OCR. For analysis in cells, HDF cells were transfected with negative control 
mimic or miR-210 mimic as explained above. After 24 hours treatment with normal 
or high glucose levels in normoxia or hypoxia, 30,000 cells from each condition were 
seeded onto an XF24 Cell Culture Microplate (Agilent Technologies). Basal OCR was 
analyzed using XF analyzer. 
3.13 Statistics
Differences between groups were analyzed using Student t-test, one-way ANOVA 
followed by Tukey’s post hoc test or two-way repeated measures ANOVA. P<0.05 
was considered statistically significant. All the in vitro experiments were performed at 
least 3 times. All the data are presented as mean ± standard error of the mean (SEM).
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4 RESULTS AND DISCUSSIONS
4.1 Paper-I
Triggering of a Dll4–Notch1 loop impairs wound healing in diabetes
Xiaowei Zheng*, Sampath Narayanan*, Vivekananda Gupta Sunkari*, Sofie Eliasson, 
Ileana Ruxandra Botusan, Jacob Grünler, Anca Irinel Catrina, Freddy Radtke, Cheng 
Xu, Allan Zhao, Neda Rajamand Ekberg, Urban Lendahl, and Sergiu-Bogdan Catrina. 
*equally contributed authors. 
4.1.1 Notch1 is activated in diabetic skin
As discussed earlier, Notch signaling is context-specific, “goldilocks” pathway and 
sensitive to changes in its expression levels50. Hence, it was of interest to investigate 
Notch signaling in the diabetic skin. We detected an increase in activated Notch1 
intracellular domain (N1ICD) levels in the skin of patients with diabetes and diabetic 
mice. This increase was mainly observed, but not restricted to the epidermis. Further, 
the gene expression levels of Notch targets (Hey1, Hey2, Hes1 and Hes5) were also 
upregulated in the human and mouse diabetic skin. Interestingly, the Notch ligand 
Dll4, but not Jagged1, was found to be increased in the skin of diabetic human and 
mouse skin. The preferential regulation of specific ligands for various functions in 
response to different environmental cues is typical of Notch pathway46. In addition 
several other genes regulated by the Notch pathway, assessed by a PCR array analysis 
were upregulated in the diabetic mouse skin compared to their controls. These genes 
play important roles in processes central to wound healing such as angiogenesis, dif-
ferentiation, proliferation, apoptosis and inflammation. 
4.1.2 Hyperglycemia induced Notch1 signaling impairs wound 
healing in diabetes
We have therefore investigated the Notch 1 signaling in different cells types impor-
tant for wound healing: human dermal fibroblasts (HDF), human keratinocytes and 
human dermal microvascular endothelial cells (HDMEC). Exposing these cells to 
high glucose concentration increased Notch1 signaling as reflected by increase in its 
target Hey1 expression levels in all cells studied. Moreover, this effect was specific to 
Notch1 and not the other receptors (as confirmed by the siRNA silencing of Notch1) 
was abrogated when the cells were exposed to the γ-secretase inhibitor (GSI), DAPT. 
Activation of Notch1 by high glucose had also negative effects on the migration of 
keratinocytes and fibroblasts and on the tube formation of the endothelial cells that 
are processes central for wound healing. DAPT treatment releases the inhibitory effect 
of hyperglycemia on these processes, suggesting a pivotal functional role for Notch1 
in of wound healing.
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In order to further investigate the role of activated Notch signaling in diabetic wound 
healing, two GSIs (DAPT and L-685 458) were tested locally in wounds of diabetic 
db/db mice and both improved wound healing rate. However, the GSIs did not affect 
the healing rate of non-diabetic mice suggesting that the increased Notch signaling in 
diabetic wounds are pathogenic. In non-diabetic wounds, where the Notch signaling 
is low, if any, inhibition of Notch signaling has no functional consequence. In perfect 
agreement with this other investigations have shown either no effect or delaying of 
wound healing when Notch signaling is inhibited75,76. Several processes were improved 
by Notch inhibition in diabetic wounds: increased proliferation and angiogenesis (shown 
through PCNA and lectin staining respectively). DAPT treatment was also followed 
by an increased levels of angiogenic factors such as CD31, VEGFR2 and VEGFR3 
and of chemokine and receptors which facilitate recruitment of endothelial progenitor 
cells such as SDF-1 and CXCR4. This, again, reflects the profound consequences of 
an increased Notch signaling for diabetic wounds. 
4.1.3 Notch1 activates a positive-feedback loop to amplify its 
signaling through Dll4
The increase in the mRNA levels of Dll4 in the skin of diabetic patients and mice, was 
followed by a corresponding increase in the protein levels, specifically in the epi-
dermis. Furthermore, the Dll4 expression in primary keratinocytes was increased by 
exposure to high glucose, effect that was abolished by DAPT treatment. Moreover, 
silencing Notch1, but not Notch2 and Notch3 was sufficient to abolish the induction 
of Dll4 by high glucose concentration, confirming the direct relation between Notch1 
and Dll4 in diabetes. 
4.1.4 Inhibiting Notch signaling leads to improvement in 
wound healing in diabetic mice
We further investigated the relevance of the above suggested Dll4-Notch1 loop by 
generating a mouse model where Notch1 is specifically abolished in the keratinocytes 
(KRT14-Cre;Notch1fl/fl). While the ablation of Notch1 in the epidermis did not affect 
the expression of other receptors, it significantly reduced the overall Notch signal-
ing as shown by the dramatic decrease in Hes1 and Dll4 levels. While induction of 
diabetes was followed by an expected increase in the Notch signaling in the skin of 
the wild-type mice, minimal if Notch signaling was detected in the skin of diabetic 
KRT14-Cre;Notch1fl/fl mice. Moreover, the wound healing rate in the diabetes-induced 
KRT14-Cre;Notch1fl/fl mice was higher than the corresponding diabetes-induced wild-
type mice.
These findings reveal a specific Dll4-Notch1 feedforward loop that contributes to 
impaired wound healing in diabetes. The specificity of the loop offer the basis for 
development of a specific Notch1 inhibitor to be used in therapy avoiding the poten-
tially systemically risks of a pan inhibition of Notch receptors in the skin 159.
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4.2 Paper-II
Deficiency of liver-derived insulin-like growth factor-1 (IGF-I) does not inter-
fere with the skin wound healing rate
Ileana Ruxandra Botusan*, Xiaowei Zheng*, Sampath Narayanan, Jacob Grünler, 
Vivekananda Gupta Sunkari, Freja S. Calissendorff, Ishrath Ansurudeen, Christopher 
Illies, Johan Svensson, John-Olov Jansson, Claes Ohlsson, Kerstin Brismar, Sergiu-
Bogdan Catrina. * equally contributed authors.
4.2.1 Liver-derived IGF-I does not affect cutaneous wound 
healing
IGF-I promotes wound healing through its pleiotropic effects on endothelial  progenitor 
migration and keratinocyte and fibroblast proliferation. However, the relative contribu-
tions of locally secreted IGF-I and systemic IGF-I produced by the liver is not character-
ized. To that end, we generated a liver-specific IGF-I knockout mice (LI-IGF-I-/-) by a 
Mx-cre 31 interferon inducible mouse model160,161. These mice had a 75% reduction in 
the serum IGF-I. This was followed by a compensatory increase in the serum growth 
hormone (GH) levels, which however, did not affect the expression of IGF-I, IGF-2 or 
IGF-IR in the skin. Induction of diabetes further decreased the serum IGF-I levels in 
these mice, in concordance with other observation in diabetes162,163. The wound healing 
rate in the healthy LI-IGF-I-/- mice was identical to corresponding wild-type mice. 
Diabetes was followed by a decrease in the wound healing rate of the same magnitude 
in both LI-IGF-I-/- mice and in wild-type mice. Taken together a 75% reduction of 
circulating IGF-I does not affect the wound healing rate that is in concordance with 
the lack of the effect on the postnatal body growth which is normal and was proposed 
to be affected just when the IGF1 serum levels reach 10-25%164. 
4.2.2 Processes central to wound healing are not affected by the 
deficiency of liver-derived IGF-I
The processes of angiogenesis, proliferation and inflammation were analyzed by 
immunohistochemistry. The loss of IGF-I in LI-IGF-I-/- mice did not lead to any 
significant difference in any of these processes when compared to the wild-type 
wounds. The density of granulation layer was also comparable between wild-type and 
LI-IGF-I-/- wounds. Since the Mx-cre 13 interferon inducible model also targets other 
cells like macrophages, apart from hepatocytes, the distribution of IGF-I in different 
types of cells was evaluated by the co-localization of IGF-I with markers for differ-
ent cells (CD31 for endothelial cells and CD11b for leukocytes such as macrophages, 
monocytes and lymphocytes in the epidermis). Indeed, the expression of IGF-I was 
significantly reduced in CD11b positive leukocytes in the LI-IGF-I-/- wounds com-
pared to the wild-type wounds at seven days post wounding while no difference was 
found at the beginning or at the end of the wound healing process. No difference was 
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found in the IGF-I expression in CD31 positive cells of the skin/wound. Overall, this 
study shows that a pathological decrease in the serum-derived IGF-I levels found 
in both type 1 and type 2 diabetes, probably does not contribute to impaired wound 
healing. This is important in confirming that a local delivery of IGF-I could suffice to 
improve wound healing in diabetes and could help avoid the negative consequences 
of a systemic IGF-I delivery. 
4.3 Paper-III
HypoxamiR-210 accelerates wound healing in diabetes by improving 
 mitochondrial energy metabolism
Sampath Narayanan, Sofie Eliasson, Cheng Xu, Jacob Grünler, Allan Zhao, Wan Zhu, 
Ning Xu Landén, Mona Ståhle, Ileana Ruxandra Botusan, Neda Rajamand Ekberg, 
Xiaowei Zheng*, Sergiu-Bogdan Catrina*. * equally contributed authors.
4.3.1 miR-210 is inhibited in diabetic wounds
HIF-1 is a master regulator of hypoxia in cells and it regulates more than 1000 coding 
and non-coding genes in humans. Although, we and others have shown that chemi-
cally or genetic recovering HIF function improved diabetic wound healing110,111, there 
are potential risks in targeting a large subset of factors, some of which, may not be 
relevant for wound healing. For instance, a chronic/hyper-activation of HIF-1 has 
been implicated in fibroproliferative diseases such as keloid and hypertrophic scars 
and systemic sclerosis165,166. So, it is important to find a narrower therapeutic window 
to target the hypoxia signaling machinery.
miR-210 represents an attractive target in that sense, since it is a robust target of HIF-1 
and regulates a variety of targets relevant to wound healing. We confirmed the regula-
tion of miR-210 by hypoxia-in the functionally relevant primary keratinocytes, dermal 
fibroblasts and human dermal microvascular endothelial cells in a time-dependent 
manner. However, exposing to high glucose diminished the hypoxia-induced expres-
sion of miR-210 in these cells. Similarly with the in vitro data, miR-210 was induced 
in the wounds of non-diabetic mice compared to unwounded skin, but not in the 
wounds from diabetic db/db mice. Concordantly, miR-210 expression was reduced in 
diabetic foot ulcers in diabetic patients compared to venous ulcers from age-matched 
non-diabetic subjects. 
4.3.2 Local reconstitution of miR-210 in the wounds improve 
wound healing in diabetes
In order to further dissect the role of miR-210 in diabetic wound healing, we injected a 
stabilized form of miR-210 locally on wound edges in db/db mice. The reconstitution 
of miR-210 improved wound healing specifically in the diabetic mice significantly. 
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Investigation of the wounds revealed an increase in cellular proliferation (evaluated 
by Ki67), angiogenesis (evaluated by CD31) and an overall increase in the density 
of the granulation layer. An increase in the deposition of collagen and a decrease in 
the immune cell infiltrates (evaluated by CD11b) was also observed. This is in agree-
ment with previously reported roles of miR-210 in cell proliferation, migration and 
angiogenesis128,130,167. The miR-210 targets, Iron-Suphur cluster assembly enzyme 
(ISCU) and Succinate dehydrogenase subunit D (SDHD), which were overexpressed 
in diabetic wounds were also significantly lowered by miR-210 administration. As 
mentioned earlier, these two proteins play important roles in the TCA cycle and elec-
tron transport chain and miR-210 was reported to limit the flux through mitochondria 
with secondary reduction of ROS formation, through these two targets125,168. In agree-
ment with these studies, reconstitution of miR-210 lead a normalization of oxygen 
consumption rate (OCR), which was abnormally increased in the control-treated db/
db wounds and was followed by a decrease in the ROS production in db/db wounds 
that was increased compared with the control-non diabetic wounds. 
4.3.3 miR-210 induces metabolic reprogramming in 
diabetic wounds
The majority of the fraction of the granulation tissue consists of fibroblasts. Given the 
timing of the effect of mi-210 and the important role of fibroblasts in  remodeling the 
tissue, the effect of miR-210 mimic transfection was investigated in fibroblasts exposed 
to hypoxia and high glucose. miR-210 overexpression significantly reduced the expres-
sion levels of ISCU and SDHD, which led to the normalization of OCR, consistent 
with the in vivo observation. This also led to a normalization of ROS production and 
an improvement in the overall function measured by an increase in proliferation and 
migration following miR-210 over expression. An increased oxygen consumption results 
from hypoxia and a defective response to it169. A resulting increase in ROS production 
is a systemic problem inherent to all diabetic complications, including wound heal-
ing170. Thus, our finding that miR-210 could decrease oxygen consumption and ROS 
production in diabetic wounds by modulating mitochondrial function is a promising 
therapeutic target to treat diabetic foot ulcers. 
4.4 Paper-IV
Downregulated miR-34a contributes to the increased Notch1 signaling in 
 diabetic wounds
Sampath Narayanan*, Sofie Eliasson*, Jacob Grünler, Cheng Xu, Dongqing Li, Ning 
Xu Landén, Mona Ståhle, Ileana Ruxandra Botusan, Neda Rajamand Ekberg, Xiaowei 
Zheng#, Sergiu-Bogdan Catrina#. #,* equally contributed authors.
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4.4.1 miR-34a is downregulated in diabetic foot ulcers
While the role of miR-34a is not well characterized in diabetic skin and wounds, the fact 
that miR-34a targets Notch1 and the detailed pathological activation of Notch1 in 
diabetic wounds make miR-34a, a compelling molecule to be investigated. We found 
that miR-34a expression levels in diabetic foot ulcers were significantly reduced 
compared to venous ulcers from age-matched non-diabetic controls. While miR-34a 
levels were higher in the venous ulcers compared  normal skin, DFUs showed similar 
levels of miR-34a compared to diabetic skin. Consistently, miR-34a levels were also 
reduced in the wounds from db/db mice compared to that of the non-diabetic controls.
4.4.2 Hyperglycemia inhibits miR-34a specifically in 
keratinocytes
In vitro analysis revealed that miR-34a was modulated by hypoxia or high glucose 
exclusively in keratinocytes. Interestingly, literature agrees that miR-34a is one of 
the highly expressed miRNAs in the epidermis171. In keratinocytes, miR-34a was 
induced by 48 hours of exposure to hypoxia and this upregulation was diminished 
when exposed to high glucose and hypoxia. However, the negative effect of high 
glucose on miR-34a was found exclusively in hypoxia, not in normoxia. This shows 
that miR-34a is affected not just by the cell type but also by the condition exposed. 
Clearly, in diabetic wounds, the miR-34a is regulated in opposite ways by hypoxia 
and hyperglycemia. Ultimately, this could explain the dysregulation of miR-34a in 
DFU as compared to venous ulcers. 
4.4.3 miR-34a-dependent Notch upregulation in keratinocytes
Interestingly, the high glucose mediated reduction in miR-34a levels in hypoxia is 
coupled to a gradual time-dependent increase in the levels of Notch1 in high glucose 
and hypoxia. Concomitantly, in diabetic wounds locally injected with miR-34a, the 
levels of Notch1 were significantly reduced. This shows a reciprocal regulation of 
Notch1 and miR-34a, confirming that Notch1 could be a target of miR-34a in diabetic 
wounds. This provides evidence for miR-34a repression in epidermis as causal factor 
for the activation of Notch1 signaling in diabetic wounds shown in paper-I. Future 
studies will assess the effect of miR-34a on wound healing rate and mechanism of its 
regulation in various processes of wound healing.
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